Robert S. Capon
Chairman, CEO, and Co-founder
Adenosine Therapeutics, LLC
United States of America
Robert S. Capon is a seasoned entrepreneur and CEO having been at the helm of four companies. Rob was one of three cofounders of ViroLogic, a pioneer in antiviral drug resistance testing, now a NASDAQ firm having completed an IPO (NASDAQ: MGRM). At Adenosine Therapeutics, Rob was the architect of the collaboration agreements with the University of Virginia Patent Foundation, Penn State University, Bristol Myers Squibb, Novartis and Santen. Prior to founding Adenosine Therapeutics and ViroLogic, Rob founded HJC Software, the makers of Virex, the first commercial anti-virus software for the Macintosh personal computer. He came to Charlottesville in 1996 to take the helm as the CEO of MJ Systems, a 50-person software company, where he positioned the company for a successful exit. Rob is an adjunct faculty member at the University of Virginia?s Darden School, where he teaches Transactions and Dealmaking in the Life Sciences. Rob serves as a member of the Piedmont Virginia Community College Educational Foundation. Rob has previously served as a member of the Advisory Board of the Governor Warner's Virginia Biotechnology Initiative as well as the board of the Virginia Research and Technology Advisory Commission (VRTAC), and VABio. He is a past board member of the NC Museum of Life and Science, the University of North Carolina's Moorehead Planetarium, AVIR sensors, Congregation Beth Israel, the University of Virginia Hillel Foundation, and the Virginia Discovery Museum, and was a past Fellow of the University of Virginia's Hereford Residential College. Rob has an MBA with honors from the Harvard Business School, and a B.S. in Mechanical Engineering, with highest distinction, from the University of Virginia.
Drug resistance testing, Life Sciences, Biotechnology